Machine Learning-driven Noninvasive Screening of Transcriptomics Liquid Biopsies for Early Diagnosis of Occult Peritoneal Metastases in Locally Advanced Gastric Cancer
NCT06478394 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2024-06-27
Summary
Brief Summary: Machine Learning-Driven Noninvasive Screening of Transcriptomics Liquid Biopsies for Early Diagnosis of Occult Peritoneal Metastases in Locally Advanced Gastric Cancer
Gastric cancer, commonly known as stomach cancer, is a significant health issue worldwide, especially when it progresses to an advanced stage. One of the major challenges in treating locally advanced gastric cancer (LAGC) is the detection of occult (hidden) peritoneal metastases. These metastases are cancer cells that spread to the peritoneum (the lining of the abdominal cavity) but are not easily detectable with standard imaging techniques or during surgery. Early and accurate detection of these hidden metastases can significantly improve treatment strategies and outcomes for patients.
This clinical study explores an innovative approach to tackle this problem using machine learning (ML) technology and liquid biopsies. Liquid biopsies are a noninvasive method that involves analyzing blood samples to detect cancer-related biomarkers, such as circulating tumor DNA or RNA. This study specifically focuses on the transcriptomics of liquid biopsies, which refers to the analysis of RNA molecules to understand the gene expression profiles associated with cancer.
Hypothesis
The hypothesis of this study is that machine learning algorithms can effectively analyze transcriptomics data from liquid biopsies to detect occult peritoneal metastases in patients with locally advanced gastric cancer. By doing so, this method could provide a noninvasive, accurate, and early diagnosis of metastases, which are otherwise difficult to identify through traditional methods.
Study Design
1. Participants: The study will enroll patients diagnosed with locally advanced gastric cancer. These patients will undergo standard diagnostic and staging procedures to confirm their cancer stage and overall health status.
2. Sample Collection: Blood samples will be collected from the participants at various stages of their treatment journey. These samples will be processed to extract RNA, which will then be analyzed to obtain transcriptomic data.
3. Machine Learning Analysis: Advanced machine learning algorithms will be employed to analyze the transcriptomic data from the liquid biopsies. The algorithms will be trained to identify patterns and markers associated with occult peritoneal metastases. The models will be continuously refined and validated using a subset of the collected data to ensure accuracy and reliability.
4. Comparison with Traditional Methods: The results of the machine learning analysis will be compared with the outcomes of traditional diagnostic methods, such as imaging and surgical examinations, to evaluate the effectiveness of the ML-driven approach.
5. Outcome Measures: The primary outcome measure will be the accuracy of the machine learning models in detecting occult peritoneal metastases compared to traditional methods. Secondary measures will include the impact of early detection on treatment decisions, patient outcomes, and overall survival rates.
Significance
Early and accurate detection of occult peritoneal metastases in locally advanced gastric cancer is crucial for effective treatment planning. Traditional diagnostic methods often fail to identify these hidden metastases until they have progressed, limiting the treatment options and adversely affecting patient prognosis. By leveraging machine learning technology to analyze transcriptomics data from liquid biopsies, this study aims to develop a noninvasive and reliable screening tool that can detect these metastases at an earlier stage.
Such an advancement could lead to several benefits, including:
* Improved Treatment Planning: Early detection allows for more tailored and effective treatment strategies, potentially including more aggressive therapies or surgical interventions when necessary.
* Better Patient Outcomes: With earlier and more accurate diagnosis, patients have a higher chance of receiving timely and appropriate treatments, which can improve survival rates and quality of life.
* Noninvasive Screening: Liquid biopsies are less invasive than traditional biopsy methods, reducing the physical and psychological burden on patients.
* Cost-Effectiveness: Early detection and treatment can potentially reduce the overall cost of care by preventing the need for more extensive and expensive treatments at later stages of the disease.
Conclusion
This clinical study represents a promising step forward in the fight against gastric cancer. By integrating machine learning with noninvasive liquid biopsy techniques, it aims to provide a new tool for the early detection of occult peritoneal metastases, ultimately improving outcomes for patients with locally advanced gastric cancer. The success of this study could pave the way for broader applications of machine learning in cancer diagnostics and personalized medicine.
Conditions
- 1. Locally Advanced Gastric Cancer (LAGC): The Primary Condition Under Investigation is Locally Advanced Gastric Cancer, Which Refers to Stomach
Interventions
- DIAGNOSTIC_TEST
-
Laparoscopic exploration
Laparoscopic exploration
Sponsors & Collaborators
-
Qun Zhao
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-30
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
NCT05140746 ·Status: RECRUITING ·Phase: NA
-
Stomach Cancer Exosome-based Detection
NCT06342427 ·Status: COMPLETED
-
Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer
NCT02327481 ·Status: COMPLETED ·Phase: NA
-
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981 ·Status: RECRUITING
-
Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
NCT06109805 ·Status: COMPLETED
-
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
NCT06235164 ·Status: ACTIVE_NOT_RECRUITING
-
Neo-adjuvant Chemotherapy Evluation in Gastric Cancer Patients Based on Circulating Exosomal LncRNA-GC1
NCT05647941 ·Status: UNKNOWN
-
A Multi-omics-based Metabolic Typing Study of Gastric Cancer
NCT06134011 ·Status: ACTIVE_NOT_RECRUITING
-
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
NCT06196554 ·Status: RECRUITING
-
Application Value of CTCs Detection for Advanced Gastric Cancer Patients
NCT03156777 ·Status: UNKNOWN
-
A Benefit Population Atlas of nICT Versus nCT for LAGC
NCT07098104 ·Status: COMPLETED
-
Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer
NCT04943406 ·Status: RECRUITING
-
Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
NCT06429891 ·Status: RECRUITING ·Phase: NA
-
A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
NCT04440605 ·Status: UNKNOWN
-
Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
NCT06791538 ·Status: RECRUITING ·Phase: NA
-
Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer
NCT04487717 ·Status: ACTIVE_NOT_RECRUITING
-
Robotic Total Gastrectomy for Locally Advanced Proximal Gastric Cancer
NCT03524287 ·Status: COMPLETED ·Phase: NA
-
Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer
NCT01625702 ·Status: COMPLETED ·Phase: NA
-
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
NCT06597227 ·Status: RECRUITING ·Phase: NA
-
Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
NCT06888037 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
NCT03468712 ·Status: UNKNOWN ·Phase: NA
-
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
NCT06202781 ·Status: RECRUITING
-
Microbiota and Metabolomics of Intestinal Type of Gastric Cancer
NCT06079554 ·Status: RECRUITING
-
Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer
NCT05497739 ·Status: UNKNOWN ·Phase: PHASE2
-
Impact of TTC Following Neoadjuvant Chemotherapy on the Prognosis of LAGC
NCT06696963 ·Status: COMPLETED